Imagine a world where some of the most aggressive cancers, once deemed untreatable, could be tackled with a new class of therapies. This is no longer just a dream, but a potential reality thanks to a groundbreaking discovery in small molecule research. Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have identified a small molecule, I3IN-002, that can inhibit a protein long considered 'undruggable'—IGF2BP3. This protein, which fuels aggressive forms of acute leukemia and other hard-to-treat cancers, has stumped researchers for decades due to its lack of traditional drug-binding sites. But here's where it gets controversial: could this discovery challenge the very foundations of how we approach cancer treatment, particularly for RNA-binding proteins? Let’s dive in.
IGF2BP3 is part of a family of RNA-binding proteins that are typically active only during the earliest stages of human development. After birth, their activity shuts down—except in certain cancers like leukemia, brain tumors, sarcomas, and breast cancers, where IGF2BP3 reactivates. For years, its lack of conventional 'pockets' or enzymatic features made it a nearly impossible target for drugs. And this is the part most people miss: by focusing on disrupting its interaction with cancer-promoting RNAs, researchers have now found a way to neutralize its harmful effects.
The study, published in Haematologica, reveals that I3IN-002 not only slows the growth of leukemic cells but also triggers their death and reduces the population of leukemia-initiating cells. This is a monumental achievement, as Dr. Dinesh Rao, the study’s senior author, explains: 'To finally show that we can inhibit this protein and disrupt its function in cancer cells is incredibly exciting.' But the journey wasn’t easy—it took over a decade of research, starting with the identification of IGF2BP3 as a key driver in acute leukemias, to develop a tool that could target it effectively.
The team employed a high-throughput screening system, testing approximately 200,000 compounds to find one that could block IGF2BP3’s interaction with its RNA targets. After identifying early candidates, they collaborated with UCLA chemistry professor Dr. Neil Garg, whose lab helped analyze the compounds’ structures and synthesize I3IN-002 in-house. Rigorous testing confirmed that the molecule specifically targets IGF2BP3, slowing leukemia cell growth, inducing apoptosis, and reducing the expression of cancer-promoting genes.
Preliminary mouse studies showed modest but measurable anti-leukemia effects, a promising start for a first-generation molecule. 'What matters most is that we proved we can hit the protein and disrupt its biology,' Rao emphasized. This breakthrough isn’t just for leukemia—it opens the door for targeting other RNA-binding proteins in cancer, a field long considered untouchable.
But here’s the controversial question: If this approach succeeds, could it revolutionize how we treat cancers driven by 'undruggable' proteins? And what does this mean for the future of personalized medicine? The team is already working on next-generation analogs of I3IN-002, aiming for greater potency and stability. As Dr. Amit Jaiswal, the study’s first author, noted, this work marks a key milestone in cancer research.
What do you think? Could this discovery be the tipping point in our fight against hard-to-treat cancers? Share your thoughts in the comments below—let’s spark a conversation that could shape the future of oncology.
